To include your compound in the COVID-19 Resource Center, submit it here.

Tetraphase's eravacycline antibiotic meets in Phase III for cIAIs

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) reported top-line data from the double-blind, international Phase III IGNITE4 trial in 500 patients with complicated intra-abdominal infections (cIAIs)

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE